OBJECTIVES: The objective of this analysis was to evaluate the cost-consequence of recombinant human growth hormone (r-hGH) administered via the easypod auto-injector versus conventional devices in children with growth hormone deficiency in Italy. METHODS: A patient level simulation, decision-analytical model was developed to estimate the average height gains and growth hormone treatment costs for a cohort of boys and girls until their bone maturation age. The calculations were performed using listed growth hormone drug prices (base case) and a scenario analysis was also conducted using published tender prices. Costs were discounted at 3%. RESULTS: Due to improved adherence and earlier identification of poor responders, patients receiving Saizen with easypod gained, on average, 3.2 cm more than patients receiving other r-hGH treatments. Saizen with Easypod had the second highest total cost including wastage (€96,710), but had the second lowest cost per centimetre gained (€7,699/cm). In the scenario analysis, Saizen with easypod had the lowest cost per cm gained (€4,708/cm) amongst all of the compared treatments. CONCLUSIONS: Saizen with easypod can be cost-saving versus all other r-hGH treatments except Omnitrope when listed drug prices are considered and can be cost-saving versus all other r-hGH treatments when tender drug prices are considered. The easypod device also facilitates cost savings in terms of reduced wastage.